首页> 外文期刊>Veterinary Evidence >Field trials and tribulations: mortality, morbidity and liveweight following multivalent clostridial and Pasteurella vaccination of lambs on six English commercial sheep flocks
【24h】

Field trials and tribulations: mortality, morbidity and liveweight following multivalent clostridial and Pasteurella vaccination of lambs on six English commercial sheep flocks

机译:田间试验和磨难:在六个英语商业绵羊群中羔羊多价梭菌和巴斯氏菌接种后的死亡率,发病率和活重疫苗

获取原文
           

摘要

Objective: This field trial aimed to assess the effect of a multivalent clostridial and Pasteurella vaccine (Heptavac P Plus, MSD Animal Health, 2015), administered to lambs at two different time points, on lamb mortality (primary outcome), morbidity and growth rates (secondary outcomes) as compared to unvaccinated lambs. Background: This veterinary practice-based study was motivated by a knowledge gap identified during flock health planning activities and engagement between veterinarians and commercial sheep producers in a regional knowledge exchange programme in South West England. Common queries to the veterinary practice from sheep producers during summer to autumn 2012 included the value and timing of vaccinations to prevent disease associated with pasteurellosis. Discussions between veterinarians and consultants working in preventive sheep flock health planning stimulated a scientific literature search, which highlighted the lack of published data on field vaccine testing of Pasteurella components under British sheep commercial farming systems, and a lack of strong evidence in order to inform practical questions regarding the optimal timing of vaccinations aimed at preventing lamb mortalities in the pre-, peri- and post-weaning periods. Evidentiary value: A field vaccine trial was conducted on six commercial sheep flocks in South West England. From April 2013, across the six farms a total of 900 twin-born lambs (Ovis aries) were systematically randomly allocated into 1. unvaccinated, 2. early- (6 to 8-week-old) or 3. late- (18 to 20-week-old) vaccination groups. The study provides evidence to support recommendations for sheep producers regarding risks for clostridial disease in fully unvaccinated sheep flocks, supports the benefits of preventive ewe vaccination, and indicates that pre-weaning vaccination of lambs may be beneficial for reducing peri- and post-weaning losses on some flocks. The study highlights the challenges of identifying the reasons for mortality in grazing lambs, and provides new evidence to support the need for early intervention and treatment of ocular lesions in young lambs, in order to reduce their negative impact on lamb performance. Methods. During the 6-month trial, lambs were assessed for ocular lesions, orf lesions, clinical respiratory disease, lameness, diarrhoea, and ear tag losses. Monthly liveweights (kg) and mortalities were recorded. Lambs were removed from the study when they reached producer-defined finishing objectives, ≥46 kg liveweight or when they died. Results: Overall, low levels of mortality and disease outcomes were observed in both control and vaccinated lambs. A mortality rate of 33 deaths per 1000 lambs at-risk, 0.8% lameness (95% CI 0.6–1.1), 1.7% diarrhoea (95% CI 1.4–2.2), 3% ocular disease (including ocular discharge and/or entropion) (95% CI 2.2–3.2), and 2.6% orf lesions (95% CI 2.2–3.1) were recorded over the trial period. A higher proportion of mortalities occurred in unvaccinated or partially vaccinated lambs (n=23; 76.7%), as compared to trial lambs that had received a primary vaccine course (n=7; 13.3%). A small proportion of mortalities (n=3; 10.0%) occurred in lambs whose vaccination status could not be confirmed No clinical signs of respiratory disease were recorded during veterinary or producer assessments of control or vaccinated trial lambs. Mixed-effects models found significant between-farm and time differences in liveweights (p0.001) but no significant effect of vaccination status on lamb growth rates. A dramatic decrease in lamb growth rates across all farms coincided with the weaning period – this was also the period in the study were the majority of grazing lamb mortalities were identified in flocks that routinely vaccinated their ewes against clostridial disease and pastuerellosis. Conclusion: A clear trend was found with fewer mortalities occurring in lambs that received a multivalent clostridial and Pastuerella spp. vaccination course compared to unvaccinated lambs. The reasons behind mortalities in grazing lambs were not diagnosed given the low submission of carcases for veterinary necropsy examination that was attributed to carcase scavenging and decomposition. No significant effects of vaccination were found on lamb growth rates or clinical outcomes. However, a secondary finding was the significant negative effect of ocular conditions (including discharge and entropion) on growth rates of lambs aged 6 weeks and over – supporting the need for early recognition and intervention in order to reduce animal welfare and production impacts. Application: We highlight study findings, field experiences and discuss some of the practical challenges and considerations in design and conduct of field vaccine trials used to inform evidence-based veterinary practice. The study will be of interest to veterinary surgeons, sheep producers, flock health and agricultural consultants, pharmaceutical agencies and advisors, researchers and those
机译:目的:旨在评估价梭菌和巴氏杆菌疫苗(Heptavac八方,MSD动物保健,2015年)的效应田间试验,在两个不同的时间点被施用羔羊,对羔羊的死亡率(主要成果),发病率和增长率(二次结果)与未被接种的羊羔相比。背景:基于兽医实践的研究是通过在群卫生规划活动期间确定的知识差距,以及在英格兰西南部地区知识交流计划中的兽医和商业羊生产者之间的参与。 2012年夏季到秋季绵羊生产者兽医练习的普通查询包括疫苗接种的价值和时间,以防止与巴斯特脲症相关的疾病。讨论预防绵羊群健康规划中的兽医和顾问的讨论刺激了一个科学文献搜索,突出了英国羊商业农业系统下缺尿菌组件的缺乏现场疫苗测试的公布数据,缺乏有力的证据,以便提供信息关于旨在防止羊羔死亡期的疫苗接种疫苗中的最佳时间问题。证据价值:在英格兰西南部的六个商业绵羊群中进行了现场疫苗试验。从2013年4月开始,六个农场共有900个双出生的羊羔(OVI ARIES)被系统地随机分配到1.未被移到1。早期 - (6至8周龄)或3.迟到 - (18至20周龄)疫苗接种群体。该研究提供了证据支持对羊毛疾病风险的绵羊生产者的建议,支持预防eWE疫苗的益处,并表明羊羔预防疫苗接种可能有利于减少断奶和断奶后损失在一些群。该研究突出了鉴定放牧羊羔中死亡率原因的挑战,并提供了新的证据,以支持年轻羊羔早期干预和治疗眼病变的需要,以减少对羔羊性能的负面影响。方法。在6个月的试验期间,评估了羔羊的眼病变,ORF病变,临床呼吸道疾病,跛行,腹泻和耳标损失。每月活力重量(千克)和死亡人数被记录。当他们达到生产者定义的精加工目标时,羔羊被从研究中移除,≥46公斤的活重或死亡时。结果:对照和疫苗接种羊丸管,观察到总体,降低死亡率和疾病结果。每1000只羊羔的死亡率为33例,跛足,0.8%跛足(95%CI 0.6-1.1),1.7%腹泻(95%CI 1.4-2.2),3%眼部疾病(包括眼部排放和/或熵) (95%CI 2.2-3.2),并在试用期内记录2.6%ORF病变(95%CI 2.2-3.1)。死亡率较高比例的发生在未接种疫苗或接种疫苗的部分羊羔(N = 23; 76.7%),相比于已收到主疫苗当然试验羔羊(N = 7; 13.3%)。在羊羔中发生少量死亡(n = 3; 10.0%),其疫苗接种状态无法确认,在对照或疫苗接种的试验羔羊的兽医或生产者评估期间没有记录呼吸系统疾病的临床迹象。混合效应模型在活重的农场和时间差异之间发现了显着的(P <0.001),但疫苗接种状态对羊羔生长率没有显着影响。所有农场的羊羔增长率的急剧下降恰逢断奶时期 - 这也是研究中的一段时间是大多数放牧羔羊死亡的羊群中被鉴定在植物中,常规接种他们的母羊对梭菌疾病和面糊症的母鸡。结论:在羊羔中发现了明确的趋势,羔羊发生了较少的死亡率,接受多价梭菌和巴特脲SPP。疫苗接种课程与未被接种的羊羔相比。在患有尸体尸体检查的尸体患者患者归因于尸体清除和分解,未被诊断出现在放牧羊羔的原因。在羊羔生长率或临床结果中没有发现疫苗接种的显着效果。然而,二次发现是眼部条件(包括放电和熵)对6周龄羔羊生长率的显着负面影响,并过度支持早期识别和干预的需要,以减少动物福利和生产影响。申请:我们强调了研究结果,现场经验,并讨论了用于向基于证据的兽医实践提供信息的现场疫苗试验的一些实际挑战和考虑因素。该研究将对兽医外科医生,绵羊生产者,羊群健康和农业顾问,制药机构和顾问,研究人员和那些感兴趣

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号